Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q1 FY27
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q3 FY25
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
569.15 | 7,075 Cr | 31.89 | 15.15 | 0.79 | 47.50 | 52.11 | 32.88 | ||
215.00 | 6,974 Cr | 4.49 | 5.21 | 0.00 | 116.01 | 80.89 | 71.55 | ||
845.50 | 6,799 Cr | 32.51 | 5.68 | 0.12 | 17.46 | 23.00 | 15.41 | ||
417.80 | 6,794 Cr | 24.14 | 2.73 | 1.20 | 11.32 | 15.18 | 9.64 | ||
1411.50 | 6,500 Cr | 56.34 | 6.96 | 0.00 | 12.36 | 14.43 | 7.58 | ||
685.65 | 6,217 Cr | 33.34 | 2.93 | 0.51 | 8.22 | 9.59 | 5.36 | ||
975.00 | 5,527 Cr | 39.22 | 5.07 | 0.21 | 12.92 | 14.30 | 7.67 | ||
| Median: 7 Co. | — | 685.65 | 6,794 Cr | 32.51 | 5.21 | 0.21 | 12.92 | 15.18 | 9.64 |
Senores Pharmaceuticals Ltd (SENORES) is currently trading at 1,315.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Senores Pharmaceuticals Limited primarily engages in developing and manufacturing pharmaceuticals for regulated markets such as the US and Canada, along with emerging markets. It has built a robust regimen of ANDAs, facilitating entry in niche, high-complexity therapeutic areas. Significantly increased its portfolio to 46 approved ANDAs covering 137 strengths, reflecting a scaling up of operations and strategic market penetration. Expected launches from pending ANDAs promise further growth. The acquisition of a 75% stake in Apnar Pharmaceuticals has strengthened Senores' operational footprint in regulated markets, with benefits of existing approvals for generic formulations. The company has shown tremendous financial growth, evidenced by a 64% increase in total income in Q3FY26 YoY, supported by a focused strategy on regulated and emerging markets. Senores merges traditional pharma with modern strategies such as CDMO/CMO, optimizing both generic and branded sectors with increasing EBITDA margins through focused commercial plans.
Over the past 52 weeks, Senores Pharmaceuticals Ltd has traded between a low of ₹631.00 and a high of ₹1,509.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Senores Pharmaceuticals Ltd has a market capitalization of approximately 6,500.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Senores Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 56.34 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,500.46 Cr, Senores Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Senores Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Senores Pharmaceuticals Ltd is 56.34. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company reported consolidated total income of ₹138.0 crore in Q1 FY26, up 72% year-on-year, as stated in the provided release and investor highlights.
The results are expected in the July to August 2026 window (indicative), in line with the broader NSE and BSE results season for the quarter ended June 2026.
The Q1 FY27 earnings conference call is scheduled for Monday, July 27, 2026, at 5:15 PM IST.
The call is scheduled for July 27, 2026, starting at 05:15 PM IST to discuss the quarter ended June 30, 2026.
Senores Pharmaceuticals Limited primarily engages in developing and manufacturing pharmaceuticals for regulated markets such as the US and Canada, along with emerging markets. It has built a robust regimen of ANDAs, facilitating entry in niche, high-complexity therapeutic areas.
Significantly increased its portfolio to 46 approved ANDAs covering 137 strengths, reflecting a scaling up of operations and strategic market penetration. Expected launches from pending ANDAs promise further growth.
The acquisition of a 75% stake in Apnar Pharmaceuticals has strengthened Senores' operational footprint in regulated markets, with benefits of existing approvals for generic formulations.
The company has shown tremendous financial growth, evidenced by a 64% increase in total income in Q3FY26 YoY, supported by a focused strategy on regulated and emerging markets.
Senores merges traditional pharma with modern strategies such as CDMO/CMO, optimizing both generic and branded sectors with increasing EBITDA margins through focused commercial plans.
Pharmaceuticals & Biotechnology
Pharmaceuticals
6,057 Cr
Moderate Risk
52.5
37.2
1.6
7.0
1,509.20
631.00
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
4
Neutral
3
Bullish
7
Bearish
23
Neutral
3
Bullish
20
Bearish
19
Neutral
0
Bullish
13
Financial Results
Senores Pharmaceuticals published newspaper extracts of unaudited standalone and consolidated financial results for quarter ended June 30, 2026, published in Financial Express on July 28, 2026.
Earnings Call/Transcript
Senores Pharmaceuticals Ltd: audio recording of the earnings conference call for quarter ended June 30, 2026, held on July 27, 2026, is available on the company website.
Earnings Call/Transcript
Senores Pharmaceuticals informs that the audio recording of its earnings conference call on the unaudited results for quarter ended June 30, 2026 (held on July 27, 2026) is available on the company's website.
Regulatory/Compliance Filing
Senores Pharmaceuticals Ltd submitted statement for quarter ended Jun 30, 2026 confirming no deviation in utilisation of Rs.95.00 Cr raised via preferential issue of 11,70,000 convertible equity warrants. Reviewed by Audit Committee and Board on July 27, 2026.
Regulatory/Compliance Filing
Senores Pharmaceuticals Ltd submitted statement for the quarter ended 2026-06-30 confirming no deviation in utilisation of Rs.95,00,40,000 raised via preferential issue of 11,70,000 convertible warrants. Reviewed by Audit Committee and Board on 2026-07-27.
Regulatory/Compliance Filing
Senores Pharmaceuticals submitted its statement of deviation/variation in utilisation of IPO proceeds for quarter ended June 30, 2026, reporting no deviation; reviewed by the Audit Committee and approved by the Board on July 27, 2026.
